- Home
- CRVS
as 04-25-2025 4:00pm EST
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 206.5M | IPO Year: | 2016 |
| Target Price: | $15.67 | AVG Volume (30 days): | 906.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.43 - $10.00 | Next Earning Date: | 05-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Corvus Pharmaceuticals Inc. News
CRVS Breaking Stock News: Dive into CRVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Insider Monkey
4 days ago
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?
GlobeNewswire
17 days ago
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
Thomson Reuters StreetEvents
a month ago
Q4 2024 Corvus Pharmaceuticals Inc Earnings Call
Simply Wall St.
a month ago
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit
MT Newswires
a month ago
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating
GuruFocus.com
a month ago
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Associated Press Finance
a month ago
Corvus: Q4 Earnings Snapshot
Compare CRVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVS Corvus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.